Edition:
United States

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

24.16USD
21 Jul 2017
Change (% chg)

$-0.16 (-0.66%)
Prev Close
$24.32
Open
$24.49
Day's High
$24.53
Day's Low
$23.83
Volume
2,021,339
Avg. Vol
365,741
52-wk High
$32.54
52-wk Low
$15.15

Latest Key Developments (Source: Significant Developments)

Myriad Genetics agree on new long-term relationship with UnitedHealthcare
Wednesday, 21 Jun 2017 09:19am EDT 

June 21 (Reuters) - Myriad Genetics Inc :Myriad genetics inc - on june 19, agreed on a new long-term relationship with unitedhealthcare - sec filing.Myriad genetics inc - new product coverage will be determined based on a member's benefit plan, additional terms of deal are not disclosed.Myriad genetics inc - relationship established pricing for its hereditary cancer tests, genesight, prolaris, vectra da and endopredict.  Full Article

Agena Bioscience announces expanded partnership with Assurex Health
Tuesday, 20 Jun 2017 08:13am EDT 

June 20 (Reuters) - Myriad Genetics Inc :Agena bioscience - assurex health, subsidiary of myriad genetics, has selected massarray system for streamlined laboratory set-up, sample processing of assurex health's genesight test.Agena bioscience - under new partnership, assurex health expects to significantly increase number of genesight test samples run on the massarray system.  Full Article

Myriad Genetics announces results from a large 2,000 patient clinical utility study of its myRisk Hereditary Cancer Test
Friday, 2 Jun 2017 07:05am EDT 

June 2 (Reuters) - Myriad Genetics Inc :Myriad Genetics Inc announces results from a large 2,000 patient clinical utility study of its myRisk Hereditary Cancer Test.Myriad Genetics - ‍key findings are that more than 50 percent of mutations identified were in patients who would not meet current testing guidelines​.Myriad Genetics-34 percent mutations identified in unexpected genes, confirming use of multi-gene panel testing to improve hereditary cancer-risk assessment.  Full Article

Myriad Genetics reports Q3 adj earnings per share $0.27
Tuesday, 2 May 2017 04:05pm EDT 

May 2 (Reuters) - Myriad Genetics Inc :Myriad Genetics reports fiscal third-quarter 2017 financial results.Q3 adjusted earnings per share $0.27.Q3 gaap earnings per share $0.06.Q3 revenue $196.9 million versus i/b/e/s view $189.1 million.Q3 earnings per share view $0.23 -- Thomson Reuters I/B/E/S.Myriad Genetics Inc sees fiscal year 2017 revenue in the range of $763 million to $765 million.Myriad Genetics Inc sees 2017 gaap earnings per share $0.23-$0.25.Myriad Genetics Inc sees 2017 non-gaap earnings per share $1.01-$1.03.Fy2017 earnings per share view $0.99, revenue view $751.5 million -- Thomson Reuters I/B/E/S.  Full Article

Myriad Genetics, Clovis Oncology sign agreement for use of FDA-approved BRACAnalysis CDx test
Thursday, 27 Apr 2017 07:05am EDT 

April 27 (Reuters) - Myriad Genetics Inc ::Myriad Genetics and Clovis oncology sign agreement for use of FDA-approved BRACAnalysis CDX® test to identify patients with Germline BRCA mutations for Rubraca® (rucaparib) treatment.Says financial terms of deal were not disclosed..Myriad genetics inc- under deal,myriad will submit supplementary premarket approval application for bracanalysis cdx to include rubraca.  Full Article

Myriad Genetics, Beigene sign agreement
Thursday, 6 Apr 2017 07:05am EDT 

Myriad Genetics Inc : Myriad Genetics and Beigene sign agreement to develop companion diagnostics for use with Beigene's novel parp inhibitor, BGB-290 . Myriad Genetics Inc - specific terms of deal were not disclosed. .Myriad Genetics-under deal Beigene to use co's mychoice HRD, bracanalysis CDX companion diagnostic tests to support clinical development of BGB-290.  Full Article

Myriad Genetics publishes study evaluating its myPath melanoma test
Wednesday, 5 Apr 2017 07:05am EDT 

Myriad Genetics Inc - : Myriad Genetics -published third clinical validation study and second clinical utility study for its mypath melanoma test . Myriad Genetics Inc says will submit reimbursement dossier to medicare and private insurers three months earlier than expected .Myriad Genetics-3rd clinical validation study shows mypath melanoma test had overall diagnostic accuracy of 95 percent to differentiate melanoma from benign lesions.  Full Article

Myriad Genetics director Henderson buys 6,000 shares of co's common stock on Feb 22-23
Thursday, 23 Feb 2017 11:27am EST 

Myriad Genetics Inc :Myriad Genetics Inc director John Henderson reports purchase of 6,000 shares of co's common stock on Feb 22-23 - SEC filing.  Full Article

Myriad Genetics reports fiscal Q2 2017 financial results
Tuesday, 7 Feb 2017 04:05pm EST 

Myriad Genetics Inc : Myriad Genetics reports fiscal second-quarter 2017 financial results . Q2 adjusted earnings per share $0.26 . Q2 GAAP earnings per share $0.09 . Q2 revenue $196.5 million versus I/B/E/S view $189.7 million . Q2 earnings per share view $0.24 -- Thomson Reuters I/B/E/S . Myriad Genetics Inc sees FY 2017 GAAP revenue $745-$755 million . Myriad Genetics Inc sees FY 2017 GAAP diluted earnings per share $0.31-$0.36 . Myriad Genetics Inc sees FY 2017 adjusted earnings per share $1.00-$1.05 . Myriad Genetics Inc sees Q3 revenue $188-$190 million . Myriad Genetics Inc sees Q3 GAAP diluted earnings per share $0.08-$0.10 . Myriad Genetics Inc sees Q3 adjusted earnings per share $0.23-$0.25 . Q3 earnings per share view $0.25, revenue view $190.2 million -- Thomson Reuters I/B/E/S .FY2017 earnings per share view $0.98, revenue view $751.8 million -- Thomson Reuters I/B/E/S.  Full Article

Myriad Genetics says entered into credit agreement for $300 mln on Dec.23-SEC filing
Wednesday, 28 Dec 2016 11:51am EST 

Myriad Genetics Inc : On Dec. 23, 2016, entered into a credit agreement - SEC filing . Senior secured revolving credit facility in an aggregate principal amount of up to $300 mln-SEC filing .Credit facility matures on Dec. 23, 2021.  Full Article

BRIEF-Agena Bioscience announces expanded partnership with Assurex Health

* Agena bioscience - assurex health, subsidiary of myriad genetics, has selected massarray system for streamlined laboratory set-up, sample processing of assurex health's genesight test